Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

(2011) D. Milojkovic et al.   BLOOD

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Suboptimal responses in chronic myeloid leukemia

(2011) Elias Jabbour et al.   CANCER

Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

(2011) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

(2011) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

(2011) Elias Jabbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

(2011) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

(2011) M Pfirrmann et al.   LEUKEMIA

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

(2010) Daniela Zackova et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

(2010) Javier Pinilla-Ibarz et al.   CANCER

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Evaluating Health Outcomes in the Presence of Competing Risks

(2010) Ravi Varadhan et al.   MEDICAL CARE

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating the crude probability of death due to cancer and other causes using relative survival models

(2010) P. C. Lambert et al.   STATISTICS IN MEDICINE

Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement

(2009) Dimitrios C. Ziogas et al.   ANNALS OF EPIDEMIOLOGY

Response definitions and European Leukemianet Management recommendations

(2009) Michele Baccarani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

(2009) F. Guilhot et al.   HAEMATOLOGICA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Issues in Using Progression-Free Survival When Evaluating Oncology Products

(2009) Thomas R. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD